Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing can feel like reading a foreign language—especially when Promis Neurosciences (PMN) packs pages with clinical trial data, patent charts, and dilution risk tables. Whether you need the latest Promis Neurosciences quarterly earnings report 10-Q filing or want to confirm cash runway assumptions buried deep in the 10-K, Stock Titan’s AI has already highlighted the numbers that move the share price.
Our platform ingests every form—10-K, 10-Q, 8-K, DEF 14A, S-1—and produces plain-English explanations in minutes. Curious about Promis Neurosciences insider trading Form 4 transactions? We surface real-time alerts the moment executives report a trade, so you can track Promis Neurosciences executive stock transactions Form 4 without refreshing EDGAR all day. Need context on a sudden capital raise? The AI summary inside the 8-K pinpoints dilution impact and clinical milestone funding needs.
What investors learn here:
- Cash burn trends and R&D spend extracted from each 10-Q
- Phase 1/2 trial updates found in 8-K material events explained
- Board proposals and CEO compensation decoded from the proxy statement—perfect for anyone googling “Promis Neurosciences proxy statement executive compensation”
- Historical Promis Neurosciences SEC filings explained simply with side-by-side comparisons
You’ll still see every original document, but our AI-powered summaries, keyword search, and section-level redlining let you jump straight to the questions analysts ask on earnings calls: trial enrollment status, patent life, or dilution from at-the-market offerings. Stop scrolling through PDFs and start understanding Promis Neurosciences annual report 10-K simplified—all in one place.
Insider transaction overview: Cencora, Inc. (NYSE: COR) filed a Form 4 showing that Executive Vice President Elizabeth S. Campbell acquired company stock on 06/30/2025.
- Shares acquired: 45.611 common shares.
- Purchase price: $254.873 per share.
- Total outlay: ≈ $11.6 thousand.
- Post-transaction ownership: 14,710.141 shares held directly.
- Transaction type: Purchase through the Employee Stock Purchase Plan, exempt under Rule 16b-3(c).
No derivative securities were involved and no additional material events or financial data were disclosed. The purchase represents a routine, small-scale increase (≈0.3 % of the executive’s existing holding) and is unlikely to have a material impact on Cencora’s valuation, but it does modestly reinforce insider alignment with shareholders.
Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.
The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
What is the primary focus of Promis Neurosciences?
How does the company identify its therapeutic targets?
What makes Promis Neurosciences' approach unique?
Which neurodegenerative diseases are addressed by the company’s pipeline?
What role does computational discovery play in their strategy?
How does the company ensure transparency and robust scientific validation?
